NCT03344965: Olaparib In Metastatic Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Age: 18 Years and older (Adult), Senior)
Location of Metastases: Brain
Additional Notes: Must have one of the following mutations identified through any CLIA approved NGS panel- see trial for full list of eligible mutations
Exclusions: Patients with germline (hereditary) BRCA1/2 mutations

Comments are closed.

Up ↑